埃沃洛库马布对冠状动脉斑块组成和冠状动脉PET和CT血管学微化活性的影响

Donghee Han1, Evangelos Tzolos2, Rebekah Park1

  • 1Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA; Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, USA.

PubMed
概括

在患有大量非化斑块的患者中,Evolocumab治疗在18个月内减少了斑块脆弱性和微化活性. 这表明向更稳定的斑块表型的转变,这表明冠状动脉疾病管理的潜在好处.